Results

Total Results: 199 records

Showing results for "end stage renal".

  1. Obesity (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_2012-12-11.pdf
    January 01, 2012 - . * EndoBarrier Endoluminal Sleeve for treatment of obesity and/or type 2 diabetes Lower end of the … also increases the risk of several types of cancer including colorectal, endometrial, esophageal, renal …  Potential for High Impact: Lower end of the high-potential-impact range 1 Obesity Interventions … Based on this input, our overall assessment is that this intervention is in the high end of the high-potential-impact … Based on this input, our overall assessment is that this intervention is in the lower end of the high-potential
  2. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-insulin_executive.pdf
    September 01, 2008 - agents in patients with type 2 diabetes, insulin is required in a significant number of patients at some stage … based on few absolute events in only a few studies, in which clinical outcomes were not the primary end … All trials either excluded patients with cardiac, renal, or hepatic disease or did not report whether
  3. effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
    January 28, 2016 - (e.g., those who have experienced prior treatment failures, who have advanced cirrhosis, who have renal … chronic HCV genotype 4 infection and for treating patients with chronic HCV genotype 1 infection with end-stagerenal disease on hemodialysis. … HCV genotype 4 infection and another for treating chronic HCV genotype 1 infection in patients with end-stagerenal disease on hemodialysis.23 Merck submitted a new drug application for treating chronic HCV genotype
  4. effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
    January 01, 2015 - you couldn't fiugre out which and stratify by comparator Correct, we have added text to clarify at end … and Brand names of the FDA-approved members of the class, at least those drugs available as of the end … Use of metformin in the setting of mildtomoderate renal insufficiency. Diabetes Care. … Use of metformin in the setting of mildtomoderate renal insufficiency. … stage renal disease) a.
  5. Obesity (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
    April 17, 2012 - also increases the risk of several types of cancers including colorectal, endometrial, esophageal, renal … In December 2010, Arena Pharmaceuticals announced a plan to resubmit the lorcaserin NDA by the end … phentermine plus topiramate combination is administered daily as an oral medication. 15 In late-stage … treatment of obesity this input, our overall assessment is that these interventions are in the higher end … Based on this input, our overall assessment is that this intervention is in the lower end of the high
  6. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-medications-update_executive.pdf
    March 01, 2011 - diabetes include microvascular disease, such as retinopathy and blindness, neuropathy, nephropathy, and end-stage … literature is deficient in studies enrolling people with varying levels of underlying cardiovascular and renal
  7. effectivehealthcare.ahrq.gov/sites/default/files/pdf/cad-women-diagnosis_research-protocol.pdf
    June 06, 2011 - contrast agent used during the procedure to visualize the coronary arteries may cause anaphylaxis or renal … Lesser increase in the left ventricular ejection fraction Increase in cardiac output by enhancing end-diastolic … KQ 4: Nephrogenic systemic fibrosis was added as an adverse event associated with late-stage chronic
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/rapid-evidence-heart-disease.pdf
    October 01, 2022 - EPC methods: AHRQ End-user perspectives of rapid reviews. Rockville (MD): 2016. … Fit for purpose: perspectives on rapid reviews from end-user interviews. … observational studies comparing at least two of these treatments in patients diagnosed with CAD and stage … Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure. … observational studies comparing ≥2 treatments (PCI, CABG, or MT) in patients diagnosed with both CAD and stage
  9. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_surveillance.pdf
    August 01, 2012 - Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. … deficiency: tumor in >80% of cases Not reported Retrospective cohort study Mean dose GH at the end … Among particular groups (e.g., Prader Willi syndrome, Turner Syndrome, renal insufficiency), deaths … hypertension:61 confirmed cases; most resolved with discontinuation of drug; increased risk in Chronic Renal … In one controlled trial, mean Tanner stage improved regardless of gender, and in an analysis of three
  10. effectivehealthcare.ahrq.gov/sites/default/files/pdf/distributed-network-ambulatory-therapeutics_research.pdf
    July 01, 2009 - This report comes at the end of the initial development phase of DARTNet. … Structure The DARTNet system is readily expandable, utilizing local parallel processing and a two stage … Other factors associated with adverse safety outcomes included renal dysfunction and certain specific … for the replication and propagation of DARTNet should CINA’s involvement with DARTNet come to an end … to protect University of Minnesota and to allow for DARTNet to continue should their involvement end
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/COVID-19-pharmaceutical-treatments-rapid-review.pdf
    March 01, 2024 - Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis. … Evidence-based Practice Center (EPC) Program is developing a range of rapid evidence products to assist end-users … RR = 0.34; CI: 0.01, 8.23 Wrist fracture: 0/1109, 1/1115 RR = 0.34; CI: 0.01, 8.23 Creatinine renal … Risk Factor Analysis Risk of Bias (ROB) Selvaraj, 202149 Remdesivir in COVID-19 patients with endstage renal disease Letter to the editor Setting: Inpatient Cohort study N = 28 Population:
  12. effectivehealthcare.ahrq.gov/sites/default/files/arthritis_hi_impact.pdf
    January 01, 2014 - noted that efficacy was demonstrated, they cited safety concerns about infection, cardiovascular, and renal … times greater than the general population, and the substantial mortality is due primarily to comorbid renal … Based on this input, our overall assessment is that this intervention is in the lower end of the … Committee form, EQ VAS quality of life score) were obtained from the base-line evaluation to the end … The results remained stable from the end of the therapy to 6 months followup, before significantly
  13. effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_executive.pdf
    August 01, 2012 - ) – Hypertension • Cystic fibrosis • Depression (major depressive disorder only) • Diabetes • End-stagerenal disease • Pneumonia (including pneumococcal vaccination) • Pregnancy Studies had to include data … review; second, descriptions of the studies are organized by clinical condition as a reference for end
  14. effectivehealthcare.ahrq.gov/sites/default/files/ch-7-user-guide-to-ocer_130129.pdf
    March 29, 2012 - due to concerns regarding drug-drug interactions or metabolic problems.8 For example, patients with end-stagerenal disease are less likely to receive medications for secondary prevention after myocardial infarction
  15. effectivehealthcare.ahrq.gov/sites/default/files/01_arthritis_potential_high_impact_2012-12-10.pdf
    January 01, 2012 - scores (IKDC form, EQ VAS quality of life score) were reported between the baseline evaluation, the end … Barr virus-associated posttransplant lymphoproliferative disorder was observed in patients who had renal
  16. effectivehealthcare.ahrq.gov/sites/default/files/related_files/rapid-response-chemotherapy-dental.pdf
    July 01, 2023 - oral or dental examination performed on an inpatient basis as part of comprehensive workup prior to renal … the body’s immune system, leading to impairment of resistance to infections and other disorders.7 Renal … reviewer was unsure regarding the appropriate disposition of a study (either at the abstract or full-text stage … Response, a thorough search of the MEDLINE database compiled all relevant published studies through the end … Evidence-based Practice Center (EPC) Program using streamlined literature review methods to assist end-users
  17. effectivehealthcare.ahrq.gov/sites/default/files/pdf/ongoing-studies-evidence_research.pdf
    December 01, 2010 - to suggest factors that might predict relevance and utility of the completed study and associated end-products … when compared to the trial registration, and only 45 percent of studies were registered before the end … While many of these registries are no longer in existence, they likely set the stage for current clinical … Additionally, the time frame 20 examined in this project is at an early stage when trial registration … Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal
  18. effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd-heart-disease-children_research.pdf
    January 01, 2023 - other than non-melanoma skin cancer), HIV infection, organ transplant, liver failure or hepatic coma, end-stagerenal disease, respiratory failure, or severe congestive heart failure. … included to reduce the potential for misclassification and referred to the first 30 days after the end … The former use category began after indeterminate use ended (i.e., at 31 days after end of current use … of insurance coverage/pharmacy benefit, day before 65th birthday, or end of study period (December
  19. effectivehealthcare.ahrq.gov/sites/default/files/pdf/continuous-outcomes-quantitative-synthesis_methods.pdf
    March 01, 2011 - The summary of final key points and recommendations are presented in Table 2 at the end of this chapter … The two end points of IQR and range are not symmetric around median (or mean) if the distribution of … Allowing for uncertainty due to missing data in meta- analysis--part 1: two-stage methods. … alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal … monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal
  20. effectivehealthcare.ahrq.gov/sites/default/files/tech-brief-37-opiod-use-adults-comments.pdf
    November 03, 2020 - factors associated with opioid use, and opioid-related harms and adverse outcomes are included at the end … Next Steps Several future areas of research are identified at the end of each section throughout the … assume long-term opioid use is automatically bad, and because policymakers do not always read to the end … I am now at Stage II Renal Failure. … of ersatz expected utility model you embrace- but you lack the honesty to state clearly what your end

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: